Coronary artery disease is associated with particular change of serum metabolome: a case-control study

Marcin Kondraciuk1, Małgorzata Chlabicz2,3,4, Jacek Jamiołkowski1,5

  • 1Population Research Centre, Medical University of Bialystok, Bialystok, Poland.

Insights

Coronary artery disease (CAD) patients have lower levels of sphingomyelin 41:1 (SM 41:1) in their blood. This metabolite may aid in risk stratification and developing new therapies for cardiovascular disease.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Metabolomics

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality.
  • Metabolomics advancements offer new strategies for CVD evaluation.
  • This study explores metabolomic profiling for enhanced cardiovascular disease characterization.

Purpose of the Study:

  • To determine if metabolomic profiles can further characterize individuals with coronary artery disease (CAD).
  • To identify specific metabolites associated with the presence of CAD.

Main Methods:

  • Serum samples from 167 CAD patients and 166 controls were analyzed.
  • Liquid chromatography-tandem mass spectrometry profiled 188 metabolites.
  • Multiple linear regression models assessed associations between 132 metabolites and CAD.

Main Results:

  • Significant differences in serum metabolic profiles were observed between CAD patients and controls.
  • Sphingomyelin 41:1 (SM 41:1) was the primary metabolite independently associated with CAD.
  • SM 41:1 levels were lower in CAD patients and inversely correlated with CAD, smoking, and hypertension.

Conclusions:

  • CAD patients exhibit reduced plasma concentrations of SM 41:1 compared to healthy individuals.
  • Understanding sphingomyelin's role in CAD could lead to improved therapeutic strategies.
  • SM 41:1 may serve as a biomarker for risk stratification in CAD.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
37
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
100
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
66